Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Effaclar is a brand name for a range of over-the-counter and prescription-strength topical acne treatments developed by La Roche-Posay. The main active pharmaceutical ingredient in some Effaclar products is adapalene (a synthetic retinoid), which works by regulating skin cell turnover to prevent clogged pores and reduce acne lesions. Other formulations under the Effaclar brand include salicylic acid (a keratolytic agent that helps shed dead skin cells and reduce inflammation) and benzoyl peroxide (an antibacterial agent that reduces Propionibacterium acnes on the skin). These products are primarily indicated for mild to moderate acne vulgaris[1][2][3][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Effaclar (L'Oréal).